Zydus Lifesciences Ltd announced that it has received final approval from the US Food and Drug Administration to manufacture and market its generic version of Azithromycin tablets, which are used to treat certain bacterial infections. The US Food and Drug Administration (USFDA) approved Zydus Lifesciences’ manufacturing and marketing of Azithromycin tablets 500 mg strength, according to a regulatory filing. The drug will be produced at the group’s formulation manufacturing facility in Moraiya, Ahmedabad, it was announced.
According to the company, azithromycin is used to treat bacterial infections such as bronchitis, pneumonia, sexually transmitted diseases (STD), infections of the ears, lungs, sinuses, skin, throat, and reproductive organs. According to IQVIA MAT February 2023 data, azithromycin tablets 500 mg had annual sales of USD 20 million in the United States.